SCHEMBL25073028

SCHEMBL25073028

O=C(O)c1ncc(NS(=O)(=O)c2cnc(-c3ccc(F)cc3)s2)cn1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PTPN11 Q06124 1/20 0.44
▸ MAPT P10636 4/20 0.38
▸ KMT2A Q03164 3/20 0.38
▸ NPSR1 Q6W5P4 3/20 0.38
▸ MEN1 O00255 2/20 0.38
▸ POLB P06746 1/20 0.38
▸ CSNK2A2 P19784 1/20 0.38
▸ CSNK2A1 P68400 1/20 0.38
▸ KDM4E B2RXH2 4/20 0.36
▸ RAB9A P51151 4/20 0.36
▸ NPC1 O15118 3/20 0.36
▸ ALDH1A1 P00352 3/20 0.36
▸ HDAC1 Q13547 3/20 0.36
▸ HPGD P15428 2/20 0.36
▸ SMN1; SMN2 Q16637 2/20 0.36
▸ GLA P06280 2/20 0.36
▸ HDAC6 Q9UBN7 2/20 0.36
▸ HSP90AA1 P07900 1/20 0.36
▸ GAA P10253 1/20 0.36
▸ RORC P51449 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25072408 0.87 PTPN11 (0.51) PTPN11MAPTKMT2ANPSR1MEN1
SCHEMBL25073308 0.86 P4HTM (0.49) PTPN11MAPTKMT2ANPSR1MEN1
SCHEMBL25073315 0.85 KMT2A (0.49) PTPN11MAPTKMT2ANPSR1MEN1
SCHEMBL25073360 0.84 FABP4 (0.45) PTPN11MAPTKMT2ANPSR1MEN1
SCHEMBL25072518 0.83 PTPN11 (0.40) PTPN11MAPTKMT2ANPSR1MEN1
SCHEMBL25073318 0.83 PFKFB3 (0.53) PTPN11KMT2AMEN1POLBPFKFB3
SCHEMBL25073280 0.82 PTPN11 (0.45) PTPN11MAPTKMT2ANPSR1MEN1
SCHEMBL25073316 0.82 GAA (0.44) PTPN11MAPTKMT2ANPSR1MEN1
SCHEMBL25073205 0.82 HDAC1 (0.45) PTPN11MAPTKMT2ACSNK2A2CSNK2A1
SCHEMBL25073200 0.82 PTPN11 (0.43) PTPN11MAPTKMT2ANPSR1CSNK2A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230143250-A1 17-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 13 INHIBITORS AND METHODS OF USE THEREOF ENANTA PHARMACEUTICALS, INC. 2023-05-11 — — US disclosed
US-20230143250-A1 17-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 13 INHIBITORS AND METHODS OF USE THEREOF ENANTA PHARMACEUTICALS, INC. 2023-05-11 — — US disclosed
WO-2023023310-A1 17-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 13 INHIBITORS AND METHODS OF USE THEREOF ENANTA PHARMACEUTICALS, INC. (US) 2023-02-23 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230143250-A1 17-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 13 INHIBITORS AND METHODS OF USE THEREOF HSD17B1, HSD17B13, HSD17B3 PTPN11 3612/4885MAPT 3642/4885KMT2A 3702/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback